What You Should Know:
– Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group.
– The company plans to use this round of funding to refine its technology to fortify its extensive collection of training and validation datasets, crucial for robust AI models, deliver results even faster, and expand its scientific and commercial teams.
Democratizing Precision Medicine with Next-Gen AI
Zephyr AI is a high-growth healthcare technology company focused on revolutionizing precision medicine. Their team of world-class software engineers and biologists work together to leverage big data, cutting-edge AI, and next-generation technology to unlock transformational insights in the fight against cancer and cardiometabolic diseases.
Zephyr AI curates one of the world’s most comprehensive healthcare datasets through partnerships and proprietary data sources. Their AI algorithms are specifically designed to handle the complexities of real-world patient data, a historical challenge in the field. Unlike traditional AI solutions, Zephyr AI’s technology goes beyond predictions. It provides the biological context behind its results, offering crucial insights for drug development and treatment decisions.
“The US has the highest rate of avoidable cancer and cardiometabolic-related deaths among any high-income country. We must do better,” said Grant Verstandig, Zephyr AI’s Co-Founder and Executive Chairman. “At Zephyr AI, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data. With our world-class team, and the support of this investor group, we are deploying one of the largest clinicogenomic datasets that has unprecedented breadth across disease states and data partners. Collectively, we are now well positioned to support our mission of democratizing precision medicine, enhancing both the speed and success of clinical trials.”
